Results for this period
Full year1 October 2025–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Growth in direct-to-consumer sales, increases in new and subscription customers for healthcare products, strong sales of new and relaunched products and e-commerce promotions, and growth in overseas sales, mainly in the United States and China. Wholesale sales fell below plan due to the impact of the review of advertising investment in PERFECT ONE.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 October 2025–30 September 2026 |
| Net Sales | ¥43,455 million (YoY +5.6%) |
| Operating profit | ¥5,176 million (YoY +8.2%) |
| Ordinary income | ¥5,202 million (YoY +6.7%) |
| Profit attributable to owners of the parent | ¥3,507 million (YoY +37.3%) |
| Net income per share | ¥165.64 |
| Operating Margin | 11.9 |
| Equity ratio | End of the current fiscal period 82.9 / End of previous period 80.7 |
| Total assets | ¥30,084 million |
| Net assets | ¥24,952 million |
| Cash flows from operating activities | ¥2,725 million |
| Cash flows from investing activities | ¥-1,732 million |
| Cash flows from financing activities | ¥-1,176 million |
| Cash and cash equivalents at end of period | ¥16,973 million |
| Full-year earnings forecast | Net Sales ¥46,000 million (YoY +5.9%) / Operating profit ¥5,400 million (YoY +4.3%) / Ordinary income ¥5,430 million (YoY +4.4%) / Net income ¥3,590 million (YoY +2.4%) |
| Annual Dividend Forecast | ¥52 → ¥60（+15.4%） |
| Payout ratio | 35.4 |
| Depreciation and amortization | ¥321 million |
| Impairment loss | No expense recognized in the current period |
| Breakdown of extraordinary income (loss) | Extraordinary income Not applicable / Extraordinary loss Impairment Losses on Investment Securities ¥101 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New — companies / Excluded — companies / Company name Not applicable |
| Material subsequent events | Not applicable |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Investors and analysts |
| Issued Shares at Period-End | 21,855,200 shares issued at period-end |
| Treasury Shares at Period-End | 670,869 treasury shares at period-end |
| Factors Behind Changes in Business Performance | Growth in direct-to-consumer sales, increases in new and subscription customers for healthcare products, strong sales of new and relaunched products and e-commerce promotions, and growth in overseas sales, mainly in the United States and China. Wholesale sales fell below plan due to the impact of the review of advertising investment in PERFECT ONE. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Direct-to-consumer sales continued to grow, with increases in new and subscription customers for the healthcare products “Fun and Health” and the flagship product “Slimore Coffee.” In cosmetics, e-commerce promotions featuring new products, relaunched products and influencers performed well, while overseas sales also grew, mainly in the United States and China. Meanwhile, offline direct-to-consumer sales struggled following a review of advertising investment in “PERFECT ONE,” and wholesale sales fell below plan.